Hepatocellular carcinoma cost-effectiveness of therapy: Difference between revisions
No edit summary |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Hepatocellular carcinoma (HCC) most commonly appears in a patient with chronic viral hepatitis ([[hepatitis B]] or [[hepatitis C]], 20%) or with cirrhosis (about 80%). These patients commonly undergo surveillance with [[medical ultrasonography|ultrasound]] due to the cost-effectiveness. | |||
==References== | ==References== | ||
| Line 11: | Line 12: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Types of cancer]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Hepatology]] | |||
[[Category:Emergency medicine]] | |||
Latest revision as of 22:07, 29 July 2020
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma cost-effectiveness of therapy |
|
FDA on Hepatocellular carcinoma cost-effectiveness of therapy |
|
CDC on Hepatocellular carcinoma cost-effectiveness of therapy |
|
Hepatocellular carcinoma cost-effectiveness of therapy in the news |
|
Blogs on Hepatocellular carcinoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatocellular carcinoma cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Hepatocellular carcinoma (HCC) most commonly appears in a patient with chronic viral hepatitis (hepatitis B or hepatitis C, 20%) or with cirrhosis (about 80%). These patients commonly undergo surveillance with ultrasound due to the cost-effectiveness.